ArticleCancer discovery2019
GATA3-Controlled Nucleosome Eviction Drives
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 37 citations in OpenAlex.
- MYC-induced USP10 stabilizes SOX4 to promote thymocyte proliferation and leukemia onset in mice.Nature communications · 2026Article
- CANTAO: guiding clustering and annotation in single-cell RNA sequencing using average overlap.Molecular systems biology · 2026Article
- Utility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2026Article
- Gata3 drives miR-21-5p transcription to mitigate hyperoxia-induced lung injury, independent of CpG Island methylation.Scientific reports · 2025Article
- BET inhibitors downregulate the expression of the essential lncRNAHaematologica · 2025Article
- Genomic clustering tendency of transcription factors reflects phase-separated transcriptional condensates at super-enhancers.Nucleic acids research · 2025Article
- Regulatory mechanisms and context-dependent roles of TAL1 in T-cell acute lymphoblastic leukemia.Haematologica · 2024Article
- GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Exploring the pharmacological mechanisms of Shuanghuanglian against T-cell acute lymphoblastic leukaemia through network pharmacology combined with molecular docking and experimental validation.Pharmaceutical biology · 2023Article
- Myc-dependent dedifferentiation of Gata6Nature cell biology · 2023Article
- Mapping the two distinct proliferative bursts early in T-cell development.Immunology and cell biology · 2023Article
- Notch Partners in the Long Journey of T-ALL Pathogenesis.International journal of molecular sciences · 2023Review
- Review
- Firing up chromatin to forge T-ALL.Blood · 2022Article
- Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.Blood · 2022Article
- Myc-Interacting Zinc Finger Protein 1 (Miz-1) Is Essential to Maintain Homeostasis and Immunocompetence of the B Cell Lineage.Biology · 2022Article
- Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia.Cancer discovery · 2022Article
- Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia.Science advances · 2022Article
- Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.Nature genetics · 2022Article
- A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes.Molecular cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 3 countries.
Laura BelverInstitute for Cancer Genetics, Columbia University, New York, New York.ORCID 0000-0001-7493-7072
Alexander Y Yang *Institute for Cancer Genetics, Columbia University, New York, New York.
Robert Albero *Institute for Cancer Genetics, Columbia University, New York, New York.
Daniel HerranzRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.ORCID 0000-0003-1768-5969
Francesco G BrunduDepartment of Systems Biology, Columbia University, New York, New York.ORCID 0000-0003-2133-1426
S Aidan QuinnInstitute for Cancer Genetics, Columbia University, New York, New York.
Pablo Pérez-DuránInstitute for Cancer Genetics, Columbia University, New York, New York.
Silvia ÁlvarezInstitute for Cancer Genetics, Columbia University, New York, New York.
Francesca GianniInstitute for Cancer Genetics, Columbia University, New York, New York.
Marissa RashkovanInstitute for Cancer Genetics, Columbia University, New York, New York.
Devya GurungInstitute for Cancer Genetics, Columbia University, New York, New York.
Pedro P RochaDivision of Developmental Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.
Ramya RaviramLudwig Institute for Cancer Research, La Jolla, California.
Clara RegleroInstitute for Cancer Genetics, Columbia University, New York, New York.
Jose R CortésInstitute for Cancer Genetics, Columbia University, New York, New York.
Anisha J CookeInstitute for Cancer Genetics, Columbia University, New York, New York.
Agnieszka A WendorffInstitute for Cancer Genetics, Columbia University, New York, New York.
Valentina CordóDepartment of Pediatric Oncology/Hematology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0003-1373-513X
Jules P MeijerinkDepartment of Pediatric Oncology/Hematology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Raúl RabadanDepartment of Pharmacology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, New Jersey.
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, New York. af2196@columbia.edu.
Cancer Genetics (United States) · USPrincess Máxima Center · NLColumbia University · USColumbia University Irving Medical Center · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USJohnson University · USLudwig Cancer Research · BERutgers, The State University of New Jersey · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MSystematic pharmacological targeting of the core mechanisms responsible for maintaining cancer cell stateU54CA209997 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA, HONIG, BARRY H · 2016 to 2021
$10.9MTopology of Cancer Evolution and HeterogeneityU54CA193313 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2015 to 2020
$10.4MECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)UG1CA233332 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAI, SHENG, LEVINE, ROSS L · 2019 to 2025
$6.2MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MMolecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7M(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic DataR01CA185486 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LASORELLA, ANNA, RABADAN, RAUL · 2014 to 2017
$2.1MUncovering Evolutionary History using the Topology of Genomic Data with Applications to HIVR01GM117591 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2015 to 2018
$1.3MFunctional dissection of oncogenic enhancersR00CA197869 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI HERRANZ, DANIEL · 2017 to 2019
$747kFunctional dissection of oncogenic enhancersK99CA197869 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HERRANZ, DANIEL · 2015 to 2016
$342kNCI NIH HHS K99 CA197869NCI NIH HHS P30 CA013696NCI NIH HHS R00 CA197869NCI NIH HHS R01 CA185486NCI NIH HHS R35 CA210065NCI NIH HHS U01 CA217858NCI NIH HHS U54 CA193313NCI NIH HHS U54 CA209997NCI NIH HHS UG1 CA233332NIGMS NIH HHS R01 GM117591
Abstract
Long-range enhancers govern the temporal and spatial control of gene expression; however, the mechanisms that regulate enhancer activity during normal and malignant development remain poorly understood. Here, we demonstrate a role for aberrant chromatin accessibility in the regulation of
Indexed as
Enhancer Elements, GeneticAnimalsCell Line, TumorGATA3 Transcription FactorGene Expression Regulation, NeoplasticHEK293 CellsHumansJurkat CellsLeukemia, T-CellMiceNeoplasm TransplantationNucleosomesProto-Oncogene Proteins c-mycReceptor, Notch1GATA3 protein, humanGATA3 Transcription FactorMYC protein, humanNOTCH1 protein, humanNucleosomesProto-Oncogene Proteins c-mycReceptor, Notch1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.